SCHEMBL8548854

SCHEMBL8548854

CC(=CCO)C1=Cc2cc(-c3ccccc3)ccc2OC1

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 5/20 0.50
CCR5 P51681 6/20 0.40
HTR1A P08908 1/20 0.34
HTR2B P41595 1/20 0.34
TMEM97 Q5BJF2 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
MAOB P27338 2/20 0.34
MAOA P21397 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
MTNR1A P48039 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8548850 1.00 ALOX5 (0.50) ALOX5CCR5HTR1AHTR2BTMEM97
SCHEMBL8544473 0.82 ALOX5 (0.47) ALOX5CCR5TP53MAPTMAOB
SCHEMBL8544483 0.82 ALOX5 (0.50) ALOX5CCR5MAPTMAOBMAOA
SCHEMBL8544488 0.82 ALOX5 (0.50) ALOX5CCR5MAPTMAOBMAOA
SCHEMBL8544470 0.82 ALOX5 (0.47) ALOX5CCR5TP53MAPTMAOB
SCHEMBL8543191 0.80 ALOX5 (0.55) ALOX5CCR5TP53MAPTMAOB
SCHEMBL9161998 0.78 ALOX5 (0.47) ALOX5CCR5MAOBMAOANR1H4
SCHEMBL9161995 0.78 ALOX5 (0.47) ALOX5CCR5MAOBMAOANR1H4
SCHEMBL31538745 0.77 ALOX5 (0.57) ALOX5CCR5TP53MAPTMAOB
SCHEMBL8550221 0.75 RXRA (0.47) ALOX5MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0591046-B1 Chromene derivatives with a triene chain for use in the treatment of osteoporosis inflammatory diseases ADIR (FR) 1998-12-02 EP disclosed
US-5391569-A Treating osteoporosis, inflammatory disorders ADIR ET COMPAGNIE (FR) 1995-02-21 US disclosed
EP-0591046-A1 Chromene derivatives with a triene chain for use in the treatment of osteoporosis inflammatory diseases ADIR ET COMPAGNIE (FR) 1994-04-06 EP disclosed